Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (151-160 of 357) with videos related to

Pageof 36
Sort By:
The Oncologist|August 4, 2007
Erlotinib in non-small cell lung cancer treatment: current status and future developmentCesare Gridelli, Maria Anna Bareschino, Clorinda Schettino, et al.
Expert Opinion on Investigational Drugs|July 10, 2020
New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trialsDanilo Rocco, Vanesa Gregorc, Luigi Della Gravara, et al.
Cancers|October 14, 2023
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with ImmunotherapyDanilo Rocco, Luigi Della Gravara, Angela Ragone, et al.
The Oncologist|September 4, 2009
Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategyCesare Gridelli, Antonio Rossi, Paolo Maione, et al.
Expert Opinion on Investigational Drugs|April 7, 2010
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancerCesare Gridelli, Antonio Rossi, Maria Anna Bareschino, et al.
Expert Opinion on Pharmacotherapy|August 13, 2010
Advances in chemotherapy in advanced non-small-cell lung cancerPaolo Maione, Antonio Rossi, Paola Claudia Sacco, et al.
Plos One|April 15, 2017
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studiesJessica Davies, Manali Patel, Cesare Gridelli, et al.
Clinical Drug Investigation|September 29, 2012
First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL studyAlessandra Bearz, Rodolfo Passalacqua, Oscar Alabiso, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2008
Vulnerable and frail elderly: an approach to the management of the main tumour typesSilvio Monfardini, Cesare Gridelli, Lara M Pasetto, et al.
Molecular Cancer Therapeutics|June 21, 2008
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cellsFloriana Morgillo, Erika Martinelli, Teresa Troiani, et al.
Pageof 36

Showing results (151-160 of 357) with videos related to

Sort By:
Pageof 36
The Oncologist|August 4, 2007
Erlotinib in non-small cell lung cancer treatment: current status and future developmentCesare Gridelli, Maria Anna Bareschino, Clorinda Schettino, et al.
Expert Opinion on Investigational Drugs|July 10, 2020
New immunotherapeutic drugs in advanced non-small cell lung cancer (NSCLC): from preclinical to phase I clinical trialsDanilo Rocco, Vanesa Gregorc, Luigi Della Gravara, et al.
Cancers|October 14, 2023
Prognostic Factors in Advanced Non-Small Cell Lung Cancer Patients Treated with ImmunotherapyDanilo Rocco, Luigi Della Gravara, Angela Ragone, et al.
The Oncologist|September 4, 2009
Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategyCesare Gridelli, Antonio Rossi, Paolo Maione, et al.
Expert Opinion on Investigational Drugs|April 7, 2010
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancerCesare Gridelli, Antonio Rossi, Maria Anna Bareschino, et al.
Expert Opinion on Pharmacotherapy|August 13, 2010
Advances in chemotherapy in advanced non-small-cell lung cancerPaolo Maione, Antonio Rossi, Paola Claudia Sacco, et al.
Plos One|April 15, 2017
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studiesJessica Davies, Manali Patel, Cesare Gridelli, et al.
Clinical Drug Investigation|September 29, 2012
First-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer : analysis of the Italian patients enrolled in the SAiL studyAlessandra Bearz, Rodolfo Passalacqua, Oscar Alabiso, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2008
Vulnerable and frail elderly: an approach to the management of the main tumour typesSilvio Monfardini, Cesare Gridelli, Lara M Pasetto, et al.
Molecular Cancer Therapeutics|June 21, 2008
Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cellsFloriana Morgillo, Erika Martinelli, Teresa Troiani, et al.
Pageof 36